Previous 10 | Next 10 |
Gene editing biotech, Caribou Biosciences (NASDAQ:CRBU) has recorded the best intraday gain on Thursday after releasing Phase 1 data for its allogeneic anti-CD19 CAR-T cell therapy, CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma. Noting the favorable early results, SVB Leerink h...
Allogeneic CAR T Pioneer Highest Ranked Bay Area Biotech in the Large Company Category Based on Employee Survey SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the develo...
Allogene Therapeutics, Inc. (ALLO) Q1 2022 Earnings Conference Call May 04, 2022 05:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - EVP of Research and Development and Chief Medical Officer Eric...
Allogene Therapeutics press release (NASDAQ:ALLO): Q1 GAAP EPS of -$0.56 beats by $0.02. Ended First Quarter with $733 Million in Cash, Cash Equivalents and Investments Outlook: Allogene continues to expect full year GAAP Operating Expenses to be between $360 million and $390 million inc...
Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R/R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale Clinical Updates from the CD19...
New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its Operations for its Next Stage of Growth SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotec...
The U.S. FDA has granted Orphan Drug Designation to Allogene Therapeutics' (NASDAQ:ALLO) multiple myeloma candidate ALLO-605. The allogeneic CAR T asset is currently in phase 1 targeting B cell maturation antigen (BCMA). ALLO-605 was granted Fast Track status in Q2 2021. Allogene (ALLO) ...
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) pro...
ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021 ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMA BCMA Program Clinical Updates are Planned for Late 2022 SOUTH SAN FRANCISCO, Calif., Apri...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren’t found and...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...